A Florida-based operator of cannabis assets is at the center of the marijuana industry’s latest short seller attack.

On Tuesday (December 17), a short seller group called Grizzly Research issued a report targeting Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF). It led to a double-digit drop in value for the US company.

In a statement issued on Tuesday, the management team of Trulieve asked investors to recognize that this was an attempt to alter its share price by the short researchers.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“It appears today’s report is a disingenuous attempt to manipulate Trulieve’s stock price,” Trulieve said.

Kim Rivers, CEO of the American operator, said the company is prepared to take legal action against the people behind this report.

In its report, Grizzly Research questions the methods by which Trulieve has secured financing from lenders. The report even alleges that the company represents a fraud case.

The short sellers have taken particular issue with connections between Rivers’ husband John “J.T.” Burnette and an ongoing investigation regarding an FBI corruption case in Florida.

According to a recent report from the Tallahassee Democrat, new evidence in the case prompted Burnette’s attorneys to continue the trial for at least two months.

According to the Investment Industry Regulatory Organization of Canada, shares of Trulieve faced a halt on the Canadian Securities Exchange in the early part of the trading session on Tuesday. It lasted less than 10 minutes.

Trulieve is the leading seller of medical cannabis in the Florida market. The company has also become a darling of the marijuana capital markets thanks to its performance and quarterly results.

Shares of the company currently maintain a “strong buy” recommendation on analyst aggregator site TipRanks, based on five stock ratings.

The marijuana capital market has had to contend with notorious short seller attacks by way of public reports calling on stocks to fall or even bottom out.

In one of the most infamous cases of a targeted cannabis short seller attack, this year a joint report from two bearish research firms, Quintessential Capital Management and Hindenburg Research, produced a tumult of volatility for Canadian producer Aphria (NYSE:APHA,TSX:APHA).

During the 2019 edition of the Lift & Co. (TSXV:LIFT,OTCQB:LFCOF) Cannabis Business Conference in Vancouver, British Columbia, one analyst said short sellers have become attracted to the cannabis industry given its rapid rise in attention.

“It’s got probably a bit higher profile as far as opportunities for short sellers to target a particular company,” Neal Gilmer, an analyst with Haywood Securities, said at the time.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less